Gilead vs Eli Lilly (GILD vs LLY)
Gilead (GILD) vs Eli Lilly (LLY) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Gilead (GILD) and Eli Lilly (LLY) compete in healthcare and pharma. Here are Gilead and Eli Lilly side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Gilead or Eli Lilly.
Gilead vs Eli Lilly: the figures
| Figure | Gilead | Eli Lilly |
|---|---|---|
| Share price | $174.48 (November 4, 2026) | $1,417.99 (November 4, 2026) |
| Market cap | $216.4 billion | $1.26 trillion |
| P/E (TTM) | N/A | 46.0x |
| Forward P/E | 17.3x | 28.3x |
| Revenue growth (quarter) | +6.8% | +38.6% |
| Net margin (TTM) | -12.5% | 31.9% |
| Net debt / EBITDA | 1.2x | 1.0x |
| Dividend yield | 1.96% | 0.49% |
| Beta | 0.37 | 0.39 |
Gilead and Eli Lilly figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Gilead or Eli Lilly figure is not available, and we never estimate it.
3 key differences between Gilead and Eli Lilly
- Profitability: for every 100 of sales, Eli Lilly keeps 31.9 as net profit and Gilead keeps -12.5.
- Growth: Eli Lilly grew sales +38.6% year on year in its latest quarter, against +6.8% for Gilead.
- Dividend: Gilead yields 1.96% at today's price and Eli Lilly yields 0.49%.
Gilead or Eli Lilly: which fits your profile
- If you want growth: Eli Lilly is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Gilead pays the higher dividend relative to its price.
- If you prefer caution: Eli Lilly has less debt relative to its profit, which usually gives more room in a bad year.
Neither Gilead nor Eli Lilly wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Gilead and Eli Lilly make money
Gilead (GILD)
Gilead Sciences is a biotech whose largest revenue source is HIV treatment and prevention, led by Biktarvy, alongside Descovy and Yeztugo. It also sells cancer drugs, including Trodelvy and Kite's cell therapies Yescarta and Tecartus, liver disease treatments such as Epclusa and Livdelzi, and the antiviral Veklury. Full Gilead analysis.
Eli Lilly (LLY)
Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. The United States is its biggest market. Full Eli Lilly analysis.
Frequently asked questions: Gilead vs Eli Lilly
Is Gilead or Eli Lilly the better stock?
Choosing between Gilead and Eli Lilly depends on what you are looking for. Eli Lilly is growing faster right now. Fintols does not tell you whether to buy Gilead or Eli Lilly: it shows you the differences so you can decide.
Which pays a higher dividend, Gilead or Eli Lilly?
As of November 4, 2026, Gilead yields 1.96% and Eli Lilly yields 0.49%. Also check how much of their profit Gilead and Eli Lilly pay out: if it is more than they earn, it cannot last.
Can I own both Gilead and Eli Lilly?
Yes. Many people spread their money across several companies, such as Gilead and Eli Lilly, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Gilead or Eli Lilly.
More comparisons with Gilead or Eli Lilly
More companies like Gilead and Eli Lilly: healthcare and pharma stocks. Educational content about Gilead and Eli Lilly, not investment advice.